FY2025 EPS Estimates for Pfizer Boosted by Cantor Fitzgerald

Pfizer Inc. (NYSE:PFE) – Equities researchers at Cantor Fitzgerald increased their FY2025 EPS estimates for Pfizer in a note issued to investors on Wednesday, November 5th. Cantor Fitzgerald analyst C. Gould now expects that the biopharmaceutical company will post earnings of $3.20 per share for the year, up from their prior forecast of $3.05. The consensus estimate for Pfizer’s current full-year earnings is $2.95 per share. Cantor Fitzgerald also issued estimates for Pfizer’s FY2026 earnings at $3.25 EPS.

PFE has been the subject of several other research reports. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $26.00 target price on shares of Pfizer in a research report on Wednesday. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Bank of America boosted their price objective on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. UBS Group restated a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. Finally, Citigroup lifted their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $28.18.

Pfizer Stock Up 1.3%

Shares of NYSE PFE opened at $24.92 on Friday. The stock has a fifty day moving average price of $24.75 and a 200 day moving average price of $24.34. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer has a 12-month low of $20.92 and a 12-month high of $27.69. The company has a market cap of $141.68 billion, a P/E ratio of 13.26, a P/E/G ratio of 0.81 and a beta of 0.54.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS.

Hedge Funds Weigh In On Pfizer

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PFE. Cidel Asset Management Inc. increased its position in Pfizer by 2.6% in the 3rd quarter. Cidel Asset Management Inc. now owns 78,767 shares of the biopharmaceutical company’s stock valued at $2,007,000 after acquiring an additional 1,990 shares during the period. Murphy & Mullick Capital Management Corp grew its stake in shares of Pfizer by 15.8% in the third quarter. Murphy & Mullick Capital Management Corp now owns 13,482 shares of the biopharmaceutical company’s stock worth $333,000 after purchasing an additional 1,840 shares in the last quarter. MSH Capital Advisors LLC grew its stake in shares of Pfizer by 23.0% in the third quarter. MSH Capital Advisors LLC now owns 53,682 shares of the biopharmaceutical company’s stock worth $1,368,000 after purchasing an additional 10,050 shares in the last quarter. WJ Financial Advisors LLC acquired a new position in shares of Pfizer during the third quarter valued at $297,000. Finally, Omnia Family Wealth LLC raised its stake in shares of Pfizer by 15.3% during the third quarter. Omnia Family Wealth LLC now owns 11,667 shares of the biopharmaceutical company’s stock valued at $297,000 after purchasing an additional 1,548 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s payout ratio is 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.